The breast graded prognostic assessment is associated with the survival outcomes in breast cancer patients receiving whole brain re-irradiation
| Autor: | Shih-Fan Lai, Yu-Hsuan Chen, Chiun-Sheng Huang, Che-Yu Hsu, Sung-Hsin Kuo, Yen-Sen Lu, Huang-Chun Lien, Tony Hsiang-Kuang Liang |
|---|---|
| Rok vydání: | 2017 |
| Předmět: |
0301 basic medicine
Re-Irradiation Adult Cancer Research medicine.medical_specialty Neurology Receptor ErbB-2 medicine.medical_treatment Breast Neoplasms Gastroenterology Radiosurgery 03 medical and health sciences 0302 clinical medicine Breast cancer Internal medicine medicine Biomarkers Tumor Humans skin and connective tissue diseases Retrospective Studies business.industry Brain Neoplasms Middle Aged medicine.disease Prognosis Survival Analysis Confidence interval Radiation therapy 030104 developmental biology Oncology Hormone receptor 030220 oncology & carcinogenesis Disease Progression Neurology (clinical) Cranial Irradiation business Brain metastasis Transcription Factors |
| Zdroj: | Journal of neuro-oncology. 138(3) |
| ISSN: | 1573-7373 |
| Popis: | Whole brain (WB) re-irradiation for breast cancer patients with progressive brain metastasis after first-course WB radiotherapy (WBRT) is controversial. In this study, we sought to investigate the association between the molecular sub-classifications and breast-specific Graded Prognostic Assessment (GPA, which includes the Karnofsky performance status, molecular subtypes, and age as its indices) and the outcomes of breast cancer patients who received WB re-irradiation. Twenty-three breast cancer patients who received WB re-irradiation for relapsed and progressive intracranial lesions after first-course WBRT between 2004 and 2016 were retrospectively reviewed. Patients were divided according to the 4 molecular subtypes of luminal A/B (hormone receptor [HR]+/human epidermal growth factor receptor 2 [HER2]−), luminal HER2 (HR+/HER2+), HER2 (HR−/HER2+), and triple negative (HR−/HER2−). The clinical and radiological responses and survival rates after WB re-irradiation were analyzed. At 1 month after WB re-irradiation, 13 of 23 patients (56.5%) exhibited disappearance or alleviation of neurological symptoms. The median survival time after WB re-irradiation was 2.93 months (95% confidence interval [CI], 1.79–4.08). After WB re-irradiation, patients with HER2-negative tumors had poorer median survival times than those with HER2-positive tumors (2.23 vs. 3.0 months, respectively; p = 0.022). Furthermore, patients with high breast GPA scores (2.5–4.0, n = 11) had longer median survivals than those with low-scores (0–2.0, n = 12) after WB re-irradiation (4.37 vs. 1.57 months, respectively; p |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink